Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone scan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,307 result(s) found for: Bone scan. Displaying page 1 of 66.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000885-20 Sponsor Protocol Number: Ibondronate Start Date*: 2007-07-20
    Sponsor Name:academic hospital Maastricht
    Full Title: Open label study to establish the efficacy of intravenous loading doses of Ibandronate 6 mg in patients with lung cancer and skeletal metastased experiencing moderate to severe bone pain.
    Medical condition: Patients with lung cancer and malignant disease to bone.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003771-19 Sponsor Protocol Number: 2019-100 Start Date*: 2019-11-19
    Sponsor Name:Aarhus Universitetshospital
    Full Title: The effect of improved insulin sensitivity on bone turnover markers and bone biomechanical properties in persons with type 2 diabetes mellitus
    Medical condition: Type 2 diabetes mellitus Diabetic bone disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000697-74 Sponsor Protocol Number: ML20115 Start Date*: 2006-08-07
    Sponsor Name:The BONiFIN study group
    Full Title: A phase II, open label study to establish the safety and efficacy of intravenous loading dose of 3 x Bondronat 6 mg in 3 consecutive days in patients with breast cancer and skeletal metastases expe...
    Medical condition: Treatment of pain in breast cancer patients with bone metastases
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005181-31 Sponsor Protocol Number: A4091003 Start Date*: 2009-04-29
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES
    Medical condition: PAIN DUE TO BONE METASTASES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) SK (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004316-73 Sponsor Protocol Number: 3189 Start Date*: 2006-08-23
    Sponsor Name:Royal Liverpool University hospital
    Full Title: The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A ...
    Medical condition: Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003441-16 Sponsor Protocol Number: ML20570 Start Date*: 2006-12-12
    Sponsor Name:N.V. Roche S.A.
    Full Title: OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS LOADING DOSE OF 3X 6MG IBANDRONIC ACID (BONDRONAT®) DURING 3 CONSECUTIVE DAYS IN PATIENTS WITH BREAST CANCER AND SKELETAL METASTA...
    Medical condition: Metastasic bone pain in patients with breast cancer and bone metastases
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006002 Bone pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001855-12 Sponsor Protocol Number: BO 18040 Start Date*: 2004-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal ...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001854-10 Sponsor Protocol Number: BO18039 Start Date*: 2005-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001395-38 Sponsor Protocol Number: CALIPSO-study Start Date*: 2017-08-03
    Sponsor Name:AZIENDA USL DELLA VALLE D'AOSTA
    Full Title: Treatment of Metastatic prostate cancer castration resistant (mCRPC) with 223RaCl2: response evaluation with a novel tracer 68Ga-PSMA PET molecular imaging
    Medical condition: Patients mCRPC eligible to treatment with 223RaCl2
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    20.1 100000004848 10036223 Positron emission tomography LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000520-35 Sponsor Protocol Number: ASSTBS-FARM-ONC-MERIDIAN-2020 Start Date*: 2021-05-27
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Multiparametric assessment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study
    Medical condition: PATIENTS WITH BONE METASTASIS FROM PROSTATIC CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001253-41 Sponsor Protocol Number: GOIM16002-CABONESTUDY Start Date*: 2018-03-12
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: Impact of cabazitaxel on metastatic bone disease in patients with castration resistant prostate cancer previously treated with docetaxel
    Medical condition: 1. Histologically or cytologically confirmed adenocarcinoma of prostate that is resistant to hormone therapy and previously treated with a docetaxel containing regimen.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003549-18 Sponsor Protocol Number: 004/001 Start Date*: Information not available in EudraCT
    Sponsor Name:Cliniques Universitaires SAINT-LUC
    Full Title: REDUCTION OF BONE MORBIDITY USING AN ORAL BISPHOSPHONATE IN FIBROUS DYSPLASIA OF BONE (PROFIDYS Trial)
    Medical condition: Fibrous dysplasia •Study I: patients with fibrous dysplasia of bone, with bone pain intensity above 3 on a visual analogical scale from 0 to 10. •Study II: patients with fibrous dysplasia of bone...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016664 Fibrous dysplasia of bone PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003774-16 Sponsor Protocol Number: EIFFEL Start Date*: 2016-06-07
    Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie )
    Full Title: Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO®) in renal cell carcinoma patients with bone metastases
    Medical condition: Renal cell carcinoma patients with bone metastases, with or without visceral metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004513-15 Sponsor Protocol Number: Start Date*: 2005-11-28
    Sponsor Name:Univ. Prof. Dr. Christoph Zielinski
    Full Title: ASSESSMENT OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH METASTATIC BREAST CANCER SWITCHED FROM INTRAVENOUS ZOLEDRONIC ACID THERAPY TO ORAL IBANDRONATE
    Medical condition: Metastatic bone disease due to breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002180-72 Sponsor Protocol Number: ML20268 Start Date*: 2006-06-20
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: Open Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6mg in Patients with Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, with...
    Medical condition: Patients with Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-002335-28 Sponsor Protocol Number: UMCGABR40641 Start Date*: 2013-01-07
    Sponsor Name:University medical centre groningen
    Full Title: Evaluation of VEGF expression with 89Zr-bevacizumab PET scan in patients with relapsing multiple myeloma; a feasibility study
    Medical condition: patients with relapsing multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004879-13 Sponsor Protocol Number: UKF2013/12 Start Date*: 2014-12-08
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: α-RT; Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. EBRT alone in the treatment of advanced castr...
    Medical condition: Bone metastases in advanced castration resistant prostate carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002802-48 Sponsor Protocol Number: ML 18107 Start Date*: 2006-09-22
    Sponsor Name:ROCHE
    Full Title: Evaluation of efficacy and safety of i.v. and oral ibandronate in elderly patients with bone metastases from solid tumors. A randomised phase II study
    Medical condition: Treatment of bone metastases in elderly patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027484 Metastatic pain LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004430-96 Sponsor Protocol Number: 201600107 Start Date*: 2017-12-11
    Sponsor Name:University Medical Center Groningen
    Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk
    Medical condition: Testicular cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005666-37 Sponsor Protocol Number: ODX-003 Start Date*: 2016-02-26
    Sponsor Name:DexTech Medical AB
    Full Title: A randomized, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases
    Medical condition: Metastatic Castration Resistant Prostate Cancer (CRPC) and skeletal metastases
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) EE (Completed) LV (Completed) FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 26 03:08:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA